Other Events ·
Vaxart, Inc. announced 12-month safety data from a 400-participant sentinel safety cohort in its Phase 2b clinical…
VXRTVaxart, Inc.
Vaxart, Inc. announced 12-month safety data from a 400-participant sentinel safety cohort in its Phase 2b clinical trial for an oral pill COVID-19 vaccine candidate. The study reported no vaccine-related serious adverse events or sustained Grade 3 or higher adverse events in either the vaccine arm or the mRNA vaccine comparator arm. Vaxart, Inc. is a biotechnology company developing oral vaccine candidates.